ArticleScientific reports2025
Quality by design optimisation of isothermal dry particle coating for enhanced buccal permeation of vancomycin.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The formulation and manufacture of macromolecules for oral delivery present persistent challenges owing to high molecular weight, pH sensitivity and manufacturing complexity. Consequently, over 90% of FDA-approved biologics are administered by invasive methods. Buccal delivery offers a promising non-invasive alternative, as it bypasses first-pass metabolism, avoids gastrointestinal degradation, and can improve patient compliance. Here we evaluate isothermal dry particle coating (iDPC) as a scalable, solvent-free approach to enhance buccal permeation by forming ion-pair coatings on drug particles. In iDPC, centrifugal and gas-drag forces promote systematic collisions between host and guest particles, here vancomycin and L-glutamic acid, yielding uniform surface coverage that facilitates buccal permeation. This study utilised a Design of Experiments (DoE) methodology within a Quality by Design (QbD) framework to optimise iDPC processing for vancomycin, a Biopharmaceutics Classification System (BCS) Class III glycopeptide with poor oral bioavailability. A Central Composite Face (CCF) design was utilised to investigate the interactive effects of five critical process parameters (CPPs): pre-processing time, processing time, nitrogen flow rate, drum speed and amino acid concentration, on two critical quality attributes (CQAs): content uniformity and 60-minute permeation across TR146 buccal epithelium. Regression modelling identified that increases in L-glutamic acid concentration and drum speed were the key factors enhancing permeation, while processing time and drum speed were the key variables improving content uniformity. A predictive 4D design space identified operating regions with a high probability of simultaneously meeting prespecified targets (permeation ≥ 40% and RSD ≤ 5%). The models demonstrated strong fit (R
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.